In the first such case, Chinese regulators have approved a product from a global drugmaker before any other country, reflecting its desire to get hold of leading medicines and highlighting differences in regulatory processes with Western nations.
On Tuesday, China approved roxadustat, a new anaemia drug developed by AstraZeneca and Fibrogen, before the product had even been submitted to US authorities, the Wall Street Journal reports.
The Chinese food and drugs approval system is noted for often rapidly outpacing Western-style procedures. China approved 30 innovative drugs from foreign developers during the first nine months of this year, in some cases giving the green light after just weeks of review. China is on track to match 2017’s record 40 approvals, according to research by McKinsey & Co.